Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China - Takeaways - MDSpire

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

  • By

  • Xiaohui Mo

  • Xin Bing

  • Lei Hua

  • Chengyin Xu

  • Ruijiao Lei

  • Xukai Chen

  • Yang Song

  • Tianhui Chen

  • May 20, 2026

  • 0 min

Share

  • 1

    This study analyzed long-term survival rates of hematological malignancies in Taizhou, China, using data from 10,022 patients diagnosed from 2009 to 2023.

  • 2

    The overall 5-year relative survival rate for all hematological malignancies was 57.0%, with lymphoma having the highest rate at 64.4%.

  • 3

    Survival rates decreased over time, with 10-year and 15-year relative survival rates at 46.0% and 37.5%, respectively.

  • 4

    Females generally had higher survival rates than males, except for leukemia, and younger patients (<60 years) had better outcomes than older patients.

  • 5

    The findings provide essential data for public health strategies and cancer control measures in the context of increasing hematological malignancy incidence in China.

Original Source(s)

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

  • by Xiaohui Mo, Xin Bing, Lei Hua, Chengyin Xu, Ruijiao Lei, Xukai Chen, Yang Song, Tianhui Chen

  • May 20, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma